Etienne Coyaud

Dr. Etienne Coyaud is an Inserm Researcher at Lille University. His primary research focuses on protein interactions in human health and diseases, with an emphasis on proximal interactomics to investigate cancer mechanisms. During his doctoral training at Inserm U563 (now CRCT UMR1037), he developed molecular biology approaches to identify fusion proteins and subsequent functional impacts in childhood leukemias. Subsequently, he relocated to Toronto (UHN, Medical Biophysics Department, Raught Laboratory) as a postdoctoral fellow (2011-2015) and then as an associate scientist (2015-2019), where he used proximal interactomics to address multiple fundamental and pathophysiological questions. In 2019, he was awarded a Marie Curie fellowship (MSCA-IF) to join the PRISM Inserm U1192 Unit and advance his research on oncovirus mechanisms in cancers, with a focus on Merkel Cell Carcinoma. In 2020, he secured a Researcher position at the national competition of Inserm (CRCN) in the Cancerology section. Since 2023, he has also held a secondment at the Expertise Collective Department (shared time, 40%; Inserm Public Health Institute, Paris) as a project manager. This entity functions as an interface of the Inserm with the government and national agencies, through which it is solicited to provide evidence-based insights on significant public health issues, thus helping shaping efficient Public Health policies.He has supervised 2 postdoctoral fellows, 2 PhD students, 2 engineers, 2 Master 2 and 5 Master 1 students. Throughout his career, he has published over 80 articles (5,441 citations, h-index 37), obtained European (MSCA-IF), National (InCa), and Regional (i-Site, Start-AAiR) fundings as coordinator, and National grants as partner (4x ANR, LNCC). In alignment with the PRISM thematics and in collaboration with his colleagues Drs. Julien Franck and Maxence Wizstroski, he is currently establishing a research group within the unit, dedicated to investigating proteoform dynamics in glioblastoma through the combination of cutting-edges biological, chemical and analytical tools. He also works as a consultant for a biotechnology company.